Top

Published in:

Open Access 01-07-2012 | Review Article

Mixed Cerebrovascular Disease and the Future of Stroke Prevention

Authors: Mark Fisher, Vitaly Vasilevko, David H. Cribbs

Published in: Translational Stroke Research | Special Issue 1/2012

Abstract

Stroke prevention efforts typically focus on either ischemic or hemorrhagic stroke. This approach is overly simplistic due to the frequent coexistence of ischemic and hemorrhagic cerebrovascular disease. This coexistence, termed “mixed cerebrovascular disease”, offers a conceptual framework that appears useful for stroke prevention strategies. Mixed cerebrovascular disease incorporates clinical and subclinical syndromes, including ischemic stroke, subclinical infarct, white matter disease of aging (leukoaraiosis), intracerebral hemorrhage, and cerebral microbleeds. Reliance on mixed cerebrovascular disease as a diagnostic entity may assist in stratifying risk of hemorrhagic stroke associated with platelet therapy and anticoagulants. Animal models of hemorrhagic cerebrovascular disease, particularly models of cerebral amyloid angiopathy and hypertension, offer novel means for identifying underlying mechanisms and developing focused therapy. Phosphodiesterase (PDE) inhibitors represent a class of agents that, by targeting both platelets and vessel wall, provide the kind of dual actions necessary for stroke prevention, given the spectrum of disorders that characterizes mixed cerebrovascular disease.

Fisher M. The challenge of mixed cerebrovascular disease. Ann NY Acad Sci. 2010;1207:18–22.PubMedCrossRef

Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke. 1996;27:1274–82.PubMedCrossRef

Vernooij MW, Van Der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: The Rotterdam scan study. Neurology. 2008;70:1208–14.PubMedCrossRef

Cullen KM, Kocsi Z, Stone J. Pericapillary haem-rich deposits: Evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab. 2005;25:1656–67.PubMedCrossRef

Fisher M, French S, Ji P, Kim RC. Cerebral microbleeds in the elderly: A pathological analysis. Stroke. 2010;41:2782–5.PubMedCrossRef

He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA. 1998;280:1930–5.PubMedCrossRef

CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef

Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–7.PubMedCrossRef

Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.PubMedCrossRef

10.

Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30:565–72.PubMedCrossRef

11.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRef

12.

Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRef

13.

The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.CrossRef

14.

Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd. Hennerici M, Sillesen H, Zivin JA, Welch KM, SPARCL investigators. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70:2364–70.PubMedCrossRef

15.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ. rely investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660–7.PubMed

16.

Koennecke HC. Cerebral microbleeds on MRI: Prevalence, associations, and potential clinical implications. Neurology. 2006;66:165–71.PubMedCrossRef

17.

Fan YH, Zhang L, Lam WW, Mok VC, Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke. 2003;34:2459–62.PubMedCrossRef

18.

Biffi A, Halpin A, Towfighi A, Gilson A, Busl K, Rost N, Smith EE, Greenberg SM, Rosand J, Viswanathan A. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75:693–8.PubMedCrossRef

19.

Wong KS, Chang YL, Liu JY, Gao S, Lam WW. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology. 2003;60:511–3.PubMedCrossRef

20.

Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, Breteler MM. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam Scan Study. Arch Neurol. 2009;66:714–20.PubMed

21.

Ge L, Niu G, Han X, Gao Y, Wu Q, Wu H, Zhang Y, Guo D. Aspirin treatment increases the risk of cerebral microbleeds. Can J Neurol Sci. 2011;38:863–8.PubMed

22.

Ueno H, Naka H, Ohshita T, Kondo K, Nomura E, Ohtsuki T, Kohriyama T, Wakabayashi S, Matsumoto M. Association between cerebral microbleeds on T2*-weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. AJNR Am J Neuroradiol. 2008;29:1483–6.PubMedCrossRef

23.

Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology. 2009;72:171–6.PubMedCrossRef

24.

Orken DN, Kenangil G, Uysal E, Forta H. Cerebral microbleeds in ischemic stroke patients on warfarin treatment. Stroke. 2009;40:3638–40.PubMedCrossRef

25.

Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Edinburgh Stroke Study Group, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi T, Lee SH, Briley D, Rothwell PM. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke. 2010;41:1222–8.PubMedCrossRef

26.

Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002;59:193–7.PubMedCrossRef

27.

Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: Correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002;33:1536–40.PubMedCrossRef

28.

Lee SH, Bae HJ, Ko SB, Kim H, Yoon BW, Roh JK. Comparative analysis of the spatial distribution and severity of cerebral microbleeds and old lacunes. J Neurol Neurosurg Psychiatry. 2004;75:423–7.PubMedCrossRef

29.

Naka H, Nomura E, Wakabayashi S, Kajikawa H, Kohriyama T, Mimori Y, Nakamura S, Matsumoto M. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: Association with combination of stroke subtypes and leukoaraiosis. AJNR Am J Neuroradiol. 2004;25:714–9.PubMed

30.

Maia LF, Vasconcelos C, Seixas S, Magalhães R, Correia M. Lobar brain hemorrhages and white matter changes: Clinical, radiological and laboratorial profiles. Cerebrovasc Dis. 2006;22:155–61.PubMedCrossRef

31.

Görner A, Lemmens R, Schrooten M, Thijs V. Is leukoaraiosis on CT an accurate surrogate marker for the presence of microbleeds in acute stroke patients? J Neurol. 2007;254:284–9.PubMedCrossRef

32.

Gao T, Wang Y, Zhang Z. Silent cerebral microbleeds on susceptibility-weighted imaging of patients with ischemic stroke and leukoaraiosis. Neurol Res. 2008;30:272–6.PubMedCrossRef

33.

Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK. St George-Hyslop P, Rogaeva E, Black SE. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790–5.PubMedCrossRef

34.

Jeon SB, Kwon SU, Cho AH, Yun SC, Kim JS, Kang DW. Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology. 2009;73:1638–44.PubMedCrossRef

35.

Lee SH, Heo JH, Yoon BW. Effects of microbleeds on hemorrhage development In leukoaraiosis patients. Hypertens Res. 2005;28:895–9.PubMedCrossRef

36.

Yamada S, Saiki M, Satow T, Fukuda A, Ito M, Minami S, Miyamoto S. Periventricular and deep white matter leukoaraiosis have a closer association with cerebral microbleeds than age. Eur J Neurol. 2012;19:98–104.PubMedCrossRef

37.

Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Roh JK. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: Analysis of risk factors for multifocal signal loss lesions. Stroke. 2002;33:2845–9.PubMedCrossRef

38.

Fisher M. Cerebral microbleeds and white matter disease: Separated at birth? Eur J Neurol. 2012;19:2–3.PubMedCrossRef

39.

Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: Sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2011;37:75–93.PubMedCrossRef

40.

Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloidangiopathy: Murine and cellular models. Brain Pathol. 2006;16:40–54.PubMedCrossRef

41.

Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96:14088–93.PubMedCrossRef

42.

Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.PubMedCrossRef

43.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102.PubMedCrossRef

44.

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. Neuroscience. 2001;21:372–81.PubMed

45.

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm. 2004;1:24.CrossRef

46.

Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340–6.PubMedCrossRef

47.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation. 2008;5:42.PubMedCrossRef

48.

Wilcock DM, Colton CA. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neuroll Disord Drug Targets. 2009;8:50–64.CrossRef

49.

Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosci. 2004;7:954–60.PubMedCrossRef

50.

Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem. 2004;279:20296–306.PubMedCrossRef

51.

Miao J, Xu F, Davis J, Otte-Holler I, Verbeek MM, Van Nostrand WE. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol. 2005;167:505–15.PubMedCrossRef

52.

Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther. 2010;335:580–8.PubMedCrossRef

53.

Beckman N, Gerard C, Abramowski D, Cannet C, Staufenbiel M. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer’s disease: application to passive Abeta immunotherapy. J Neurosci. 2011;31:1023–31.CrossRef

54.

MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbot R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74.PubMedCrossRef

55.

Di Napoli M, Papa F. Systemic inflammation, blood pressure, and stroke outcome. J Clin Hypertens (Greenwich). 2006;8:187–94.CrossRef

56.

Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain: I. Cerebral hemorrhage Stroke. 1983;14:915–23.CrossRef

57.

Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology. 1998;51:690–4.PubMedCrossRef

58.

Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu–Asia Aging study. Stroke. 2002;33:26–30.PubMedCrossRef

59.

Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.PubMedCrossRef

60.

Ogata J, Yamanishi H, Ishibashi-Ueda H. Review: Role of cerebral vessels in ischaemic injury of the brain. Neuropathol Appl Neurobiol. 2011;37:40–55.PubMedCrossRef

61.

Dickstein DL, Walsh J, Brautigam H, Stockton Jr SD, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt Sinai J Med. 2010;77:82–102.PubMedCrossRef

62.

Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging. 2000;21:49–55.PubMedCrossRef

63.

Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:683–1689.CrossRef

64.

Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–81.PubMedCrossRef

65.

Qiu C, Xu W, Winblad B, Fratiglioni L. Vascular risk profiles for dementia and Alzheimer’s disease in very old people: a population-based longitudinal study. J Alzheimers Dis. 2010;20:293–300.PubMed

66.

Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487–99.PubMedCrossRef

67.

de Leeuw FE, Richard F, de Groot JC, van Duijn M, Hofman A, Van Gijn J, Breteler MM. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke. 2004;35:1057–60.PubMedCrossRef

68.

Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780–6.PubMed

69.

Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu–Asia aging study. JAMA. 1995;274:1846–51.PubMedCrossRef

70.

Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: The Honolulu Asia aging study. Hypertension. 2004;44:29–34.PubMedCrossRef

71.

den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, Koudstaal PJ, Breteler MM. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology. 2005;64:263–7.CrossRef

72.

DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, Jack L, Carmelli D. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999;30:529–36.PubMedCrossRef

73.

Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu–Asia aging study. Neurobiol Aging. 2000;21:57–62.PubMed

74.

Marchesi C, Paradis P, Schiffrin EL. Role of the renin–angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367–74.PubMedCrossRef

75.

Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II induced cerebral microvascular inflammation and increased blood–brain barrier permeability via oxidative stress. Neuroscience. 2010;171:852–8.PubMedCrossRef

76.

Nabika T, Cui Z, Masuda J. The stroke-prone spontaneously hypertensive rat: how good is it as a model for cerebrovascular diseases? Cell Mol Neurobiol. 2004;24:639–46.PubMedCrossRef

77.

Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab. 2008;28:1877–91.PubMedCrossRef

78.

Southard T, Brayton CF. Spontaneous unilateral brainstem infarction in Swiss mice. Vet Pathol. 2011;48:726–9.PubMedCrossRef

79.

Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997;17:7655–61.PubMed

80.

Koistinaho M, Kettunen MI, Goldsteins G, Keinänen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A. 2002;99:1610–5.PubMedCrossRef

81.

Qin Z. Newly developed angiotensin II-infused experimental models in vascular biology. Regul Pept. 2008;150:1–6.PubMedCrossRef

82.

Wakisaka Y, Chu Y, Miller JD, Rosenberg GA, Heistad DD. Spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice. J Cereb Blood Flow Metab. 2010;30:56–69.PubMedCrossRef

83.

Iida S, Baumbach GL, Lavoie JL, Faraci FM, Sigmund CD, Heistad DD. Spontaneous stroke in a genetic model of hypertension in mice. Stroke. 2005;36:1253–8.PubMed

84.

Wakisaka Y, Miller JD, Chu Y, Baumbach GL, Wilson S, Faraci FM, Sigmund CD, Heistad DD. Oxidative stress through activation of NAD(P)H oxidase in hypertensive mice with spontaneous intracranial hemorrhage. J Cereb Blood Flow Metab. 2008;28:1175–85.PubMedCrossRef

85.

Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860–8.PubMedCrossRef

86.

Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill PS, Aslam S, Wang X, Ji H, Sandberg K, Jose P, Wilcox CS. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension. 2006;48:934–41.PubMedCrossRef

87.

Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893–912.PubMed

88.

Gomis M, Sobrino T, Ois A, Millan M, Rodriguez-Campello A. Perez de la Ossa N, Rodriguez-Gonzalez R, Jimenez-Conde J, Cuadrado-Godia E, Roquer J, Davalos A. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke. 2009;40:3197–201.PubMedCrossRef

89.

Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer’s disease: role of inflammation. Neurol Res. 2003;25:642–51.PubMedCrossRef

90.

Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann N Y Acad Sci. 2002;977:65–76.PubMedCrossRef

91.

Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–44.PubMedCrossRef

92.

Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201.PubMedCrossRef

93.

Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH. Weller RO Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131–44.PubMedCrossRef

94.

Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 2008;18:253–66.PubMedCrossRef

95.

Clapham R, O’Sullivan E, Weller RO, Carare RO. Cervical lymph nodes are found in direct relationship with the internal carotid artery: significance for the lymphatic drainage of the brain. Clin Anat. 23:43–7.

96.

Wang X, Lo EH. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol. 2003;28:229–44.PubMedCrossRef

97.

Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C. Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC. PLoS One. 2011;6:e26087. Epub 2011 Oct 19.

98.

Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol. 2012 Feb 10. doi:10.1002/ana.23558. [Epub ahead of print]

99.

Del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, Wang X, Hosomi N, Mabuchi T, Koziol JA. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab. 2012 Feb 22. doi:10.1038/jcbfm.2012.11. [Epub ahead of print]

100.

Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol. 2006;59:929–38.PubMedCrossRef

101.

Guan W, Kozak A, Fagan SC. Drug repurposing for vascular protection after acute ischemic stroke. Acta Neurochir Suppl. 2011;111:295–8.PubMedCrossRef

102.

Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372–7.PubMedCrossRef

103.

Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, Fagan SC. Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol. 1996;141:40–6.PubMedCrossRef

104.

Fagan SC, Bowes MP, Lyden PD, Zivin JA. Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol. Exp Neurol. 1998;150:153–8.PubMedCrossRef

105.

Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32:1336–40.PubMedCrossRef

106.

Henning EC, Latour LL, Hallenbeck JM, Warach S. Reperfusion-associated hemorrhagic transformation in SHR rats: Evidence of symptomatic parenchymal hematoma. Stroke. 2008;39:3405–10.PubMedCrossRef

107.

Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: Relation to blood–brain barrier dysfunction. Stroke. 2007;38:1044–9.PubMedCrossRef

108.

Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, Bruno A, Fagan SC, Ergul A. Neurovascular injury in acute hyperglycemia and diabetes: A comparative analysis in experimental stroke. Transl Stroke Res. 2011;2:391–8.PubMedCrossRef

109.

Xing Y, Jiang X, Yang Y, Xi G. Hemorrhagic transformation induced by acute hyperglycemia in a rat model of transient focal ischemia. Acta Neurochir Suppl. 2011;111:49–54.PubMedCrossRef

110.

Hu Q, Ma Q, Zhan Y, He Z, Tang J, Zhou C, Zhang J. Isoflurane enhanced hemorrhagic transformation by impairing antioxidant enzymes in hyperglycemic rats with middle cerebral artery occlusion. Stroke. 2011;42:1750–6.PubMedCrossRef

111.

Winkler DT, Biedermann L, Tolnay M, Allegrini PR, Staufenbiel M, Wiessner C, Jucker M. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol. 2002;51:790–3.PubMedCrossRef

112.

Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72:634–46.PubMedCrossRef

113.

Rubin LL, Hall DE, Porter S, Barbu K, Cannon C, Horner HC, Janatpour M, Liaw CW, Manning K, Morales J, et al. A cell culture model of the blood–brain barrier. J Cell Biol. 1991;115:1725–35.PubMedCrossRef

114.

Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.PubMedCrossRef

115.

Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147–57.CrossRef

116.

Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C. Cilostazol versus aspirin for secondary ischaemic stroke prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol. 2008;7:494–9.PubMedCrossRef

117.

Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–68.PubMedCrossRef

118.

Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008;28:s39–42.PubMedCrossRef

119.

Garcia-Bonilla L, Sosti V, Campos M, Penalba A, Boada C, Sumalla M, et al. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res. 2011;1373:211–20.PubMedCrossRef

120.

Fisher M, Vasilevko V, Passos GF, Ventura C, Quiring D, Cribbs DH. Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. Stroke. 2011;42:3300–3.PubMedCrossRef

121.

Hase Y, Okamoto Y, Fujita Y, Kitamura A, Nakabayashi H, Ito H, Maki T, Washida K, Takahashi R, Ihara M. Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. Exp Neurol. 2012;233:523–33.PubMedCrossRef

122.

Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke. 2012;43:499–506.PubMedCrossRef

123.

Kato T, Sakai H, Takagi T. Nishimura Y. AJNR Am J Neuroradiol: Cilostazol prevents progression of asymptomatic carotid artery stenosis in patients with contralateral carotid artery stenting; 2012 Feb 9 [Epub ahead of print].

124.

Chuang SY, Yang SH, Chen TY, Pang JH. Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells. Eur J Pharmacol. 2011;670:419–26.PubMedCrossRef

125.

Liu S, Yang F, Yu C, Paganini-Hill A, Fisher M. Phosphodiesterase inhibitors modulate human brain microvascular endothelial cell barrier properties and response to injury. Ann Neurol. 2011;70 Suppl 15:S6.

Title: Mixed Cerebrovascular Disease and the Future of Stroke Prevention
Authors: Mark Fisher
Vitaly Vasilevko
David H. Cribbs
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Translational Stroke Research / Issue Special Issue 1/2012
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-012-0185-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mixed Cerebrovascular Disease and the Future of Stroke Prevention

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration

Chemokines and Their Receptors in Intracerebral Hemorrhage

Excitatory and Mitogenic Signaling in Cell Death, Blood–brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage

Intracerebral Hemorrhage: Mechanisms and Therapies

Astrogliosis: a Target for Intervention in Intracerebral Hemorrhage?

Depletion of GR-1-Positive Cells Is Associated with Reduced Neutrophil Inflammation and Astrocyte Reactivity after Experimental Intracerebral Hemorrhage